Shareholding is expected to rise.
The current pb ratio of the company is only 0.35, with 9.5k cash and equivalents, debt of only 1.5k, the cash value is far greater than the current market cap. The company has entrusted Bank of America for strategic restructuring consultation, even if it is sold as a shell company, it will be much higher than the current market cap. And the major shareholders of the company have a higher proportion of holdings, and the willingness to protect the interests of shareholders will be much higher than other companies, so it is natural to continue to rise. Keep holding and expect it to rise! $Achilles Therapeutics (ACHL.US)$
An idealized outcome would involve merging with a post-clinical unlisted biomedical company and moderately issuing new shares. Assuming a pb of 1 after the merger, the increase should be greater than **% based on the current stock price.
📌Pay attention to the short sell volume and ratio in the following trading days.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
北美深蓝 OP :
The short position of the stock is less than 0.1% 